胸水肺炎链球菌聚合酶链反应检测在儿童复杂性肺炎中的临床影响
该前后对照准实验队列研究纳入2016至2023年科罗拉多儿童医院因复杂性社区获得性肺炎需胸水或脓胸引流的患儿,比较肺炎链球菌PCR检测前后两个诊断时期的病原检出、抗生素使用及结局。结果显示PCR后时期病原检出率更高、 optimal治疗比例更高、至最佳抗生素和停用MRSA治疗时间更短,住院时长和再入院无差异。
要点
- 肺炎链球菌PCR后时期病原检出率73.4% vs 前时期38.9%(P < .001)。
- PCR后时期optimal治疗比例84.8% vs 53.0%(P < .001)。
- 至最佳抗生素中位时间4.9 vs 10.0天(P < .001),停用MRSA治疗中位时间1.5 vs 2.5天(P = .03)。
核心结论
- 对复杂性社区获得性肺炎患儿胸水行肺炎链球菌分子检测可显著增加微生物学诊断,并与抗生素优化及减少MRSA治疗暴露相关,提示其临床影响。
研究设计与样本
- 前后对照准实验队列研究,比较2016至2023年科罗拉多儿童医院因复杂性社区获得性肺炎需胸水或脓胸引流的住院患儿在肺炎链球菌PCR检测前时期(n = 149)与后时期(n = 79)的病原检出、抗生素使用及结局。
主要发现
- PCR后时期病原检出率73.4% vs 前时期38.9%(P < .001),主要由肺炎链球菌检出增加驱动(45.6% vs 14.1%,P < .001)。
- PCR后时期住院期间至病原检出时间更短(P < .001)。
- PCR后时期optimal治疗比例84.8% vs 53.0%(P < .001)。
- 至最佳抗生素中位时间4.9 vs 10.0天(P < .001),停用MRSA治疗中位时间1.5 vs 2.5天(P = .03)。
- 住院时长和再入院无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While Streptococcus pneumoniae (Spn) is the leading cause of pediatric complicated community-acquired pneumonia (cCAP), it is infrequently recovered by culture-based methods. We studied the real-world clinical impact of an Spn polymerase chain reaction (PCR) assay for pleural fluid. METHODS: This pre-post quasi-experimental cohort study compared pathogen detection, antibiotic usage, and outcomes in children hospitalized with cCAP requiring pleural effusion or empyema drainage at Children's Hospital Colorado between 2016 and 2023. Patients were compared across 2 diagnostic periods: pre-Spn PCR and post-Spn PCR. Cox proportional hazard models compared time from admission to pathogen detection, optimal therapy (narrowest pathogen-directed or guideline-recommended empiric therapy), and methicillin-resistant Staphylococcus aureus (MRSA) therapy discontinuation between periods. RESULTS: Compared to the pre-Spn PCR cohort (n = 149), the post-Spn PCR cohort (n = 79) was more likely to have a pathogen detected (73.4% post-PCR vs 38.9% pre-PCR, P < .001), driven by more Spn detections (45.6% vs 14.1%, P < .001). Time to pathogen detection during hospitalization was shorter in the post-Spn PCR period (P < .001). The post-PCR cohort was more likely to receive optimal therapy (84.8% vs 53.0%, P < .001), with shorter median times to optimal antibiotics (4.9 vs 10.0 days, P < .001) and MRSA therapy discontinuation (1.5 vs 2.5 days, P = .03). There were no differences in hospital length of stay or readmissions. CONCLUSIONS: Spn molecular testing of pleural fluid in children with cCAP resulted in significantly more microbiologic diagnoses and was associated with the optimization of antibiotics and decreased exposure to MRSA therapy, suggesting its clinical impact for pediatric complicated pneumonia.
引用
- Ho EC, Olson KE, Butler M, et al. Clinical Impact of Pleural Fluid Streptococcus pneumoniae Polymerase Chain Reaction Testing in Children With Complicated Pneumonia. Clin Infect Dis. 2024. PMID: 39207213. doi:10.1093/cid/ciae439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。